Navigation Links
An Evaluation of Clinical Trial Quality in Russia and Ukraine, new webinar hosted by Xtalks
Date:3/8/2013

Toronto, Canada (PRWEB) March 08, 2013

With patient recruitment rates up to twenty times faster than the West, the biopharmaceutical industry is embracing the undeniable benefits of conducting clinical trials in emerging markets such as Russia. In fact, 33% of all drugs approved by the FDA and 48% of all drugs approved by the EMEA in 2011 included data from clinical trial research conducted in this region.

Yet with benefits like this, why isn’t this number closer to 100%? For many, the enticement for conducting clinical trials in emerging markets is over shadowed by the fear of unknown regulatory and logistics requirements, prolonged study start-up times and overall clinical trial quality.

During the webinar, ClinStar CEO David Passov and QA Director Dr. Stanislav Gneushev will evaluate the quality of clinical trials being conducted in Russia / Ukraine compared to Western Europe, Eastern Europe and other Emerging Markets based on the results of recent FDA inspections conducted at clinical trial sites in these regions. In addition, they will:

  •     Discuss key elements of successful Quality Management Systems for niche CROs operating in Russia, Ukraine, Belarus and the Baltics
  •     Provide practical advice on SOP development
  •     Present training approaches for optimal coaching of clinical monitors
  •     Consider what quality assurance activities are required in Russia and parts of Eastern Europe to ensure continuous quality improvement of clinical studies

For more information about this event or to register, visit: http://xtks.in/xto580-event

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/3/prweb10499405.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PhaseRx Announces Technology Evaluation Agreement with Monsanto
2. Evaluation of a Single 1.000 mg Iron Dose as Ferric Carboxymaltose (FCM) for Fatigue Treatment in Iron Deficient Women - PREFER
3. New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation
4. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
5. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
6. Macrogen Corp. Announces the Inception of Macrogen Clinical Laboratory (MCL)
7. PhUSE Announces Open Source Repository of Clinical Trial Informatics Analysis Code
8. QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics
9. NeoClinical Launches Neo PayPerPatient Clinical Trial Recruitment
10. Eastern Clinical Trials Russia CRO Passes EMA Inspection
11. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
Breaking Biology Technology:
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):